Form 4: Karyopharm Therapeutics Executive VP Sells Shares to Cover Tax Obligations

Stuart Poulton, EVP and Chief Development Officer of Karyopharm Therapeutics, sold 3,548 shares of common stock to cover withholding tax liabilities.

Summary

• On March 4, 2025, Stuart Poulton, the EVP and Chief Development Officer of Karyopharm Therapeutics Inc., sold 3,548 shares of the company's common stock.
• The sale was executed at a weighted average price of $6.29 per share, with individual transactions ranging from $6.14 to $6.31.
• The transaction was conducted under a pre-arranged automatic sale plan adopted on May 18, 2022, to cover withholding tax obligations arising from the vesting of restricted stock units.
• Following the transaction, Poulton directly owns 27,414 shares of Karyopharm Therapeutics Inc.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (sale of shares for tax obligations) and does not contain any information that would significantly impact investor sentiment positively or negatively.

Industry Context

Sales of shares to cover tax obligations are a routine part of executive compensation and are not necessarily indicative of the executive's view of the company's future prospects.

Key Dates

Keywords

Karyopharm Therapeutics, Stuart Poulton, stock sale, Form 4, insider trading, executive compensation, withholding tax, automatic sale plan, KPTI